long-term follow-up of luspatercept: response duration and progression to aml
Published 2 years ago • 93 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
8:33
boven regimen for previously untreated cll: long-term follow-up and mrd kinetics
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
3:41
long-term follow-up: aml17 trial of ato and atra vs the standard of care in apl
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
7:08
believe: β-thalassemia treatment with luspatercept reduces transfusion burden
-
5:21
what is prothrombin time?
-
20:58
roivant r&d day immunovant fireside chat
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
2:26
ace-536-mf-001 update: luspatercept for the treatment of anemia in myelofibrosis
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
1:03
late effect surveillance following allosct: the publication of new guidelines
-
3:54
results of medalist: luspatercept reduces transfusion burden in mds
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
13:57
potential clinical utility of long-read sequencing in myeloid neoplasms
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
14:43
current research into post-allosct maintenance therapy in aml